Expression of phosphorylated mTOR and its clinical significances in small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• The mammalian target of rapamycin (mTOR) pathway regulates cell growth and protein synthesis.
• mTOR is a therapeutic target in cancers like non-small cell lung cancer (NSCLC).
• mTOR expression in small cell lung cancer (SCLC) remains under-investigated.

Purpose of the Study:

• To investigate the correlation between phosphorylated mTOR (p-mTOR) expression and clinical characteristics in SCLC patients.
• To determine if p-mTOR levels differ between limited and extensive-stage SCLC.
• To explore the relationship between p-mTOR expression and lymph node metastasis or overall survival in SCLC.

Main Methods:

• Immunohistochemical staining for p-mTOR was performed on 115 SCLC tissue specimens.
• Histoscores were calculated and a cutoff of 60 was used to categorize SCLC into low and high p-mTOR expression groups.
• Statistical analyses were conducted to compare p-mTOR expression with clinical stage, lymph node metastasis, and overall survival.

Main Results:

• Extended-stage SCLC showed significantly lower p-mTOR expression compared to limited-stage SCLC (P=0.008).
• Lymph node metastasis was more frequent in the low p-mTOR expression group (P=0.074).
• A weak, non-significant trend towards prolonged overall survival was observed in the high p-mTOR expression group (P=0.170).

Conclusions:

• Significant differences in p-mTOR expression exist between clinical stages of SCLC.
• p-mTOR may play a more critical role in the biological behavior of early-stage SCLC than advanced stages.
• The efficacy of mTOR inhibitors in SCLC treatment might be influenced by the disease's extent and p-mTOR expression levels.